aTyr Pharma

aTyr Pharma, Inc. engages in the discovery and development of medicines based on novel biological pathways. Its product pipeline includes ATYR1923, ATYR2810, NRP2 mAbs, and AARS-1, DARS-1. The company was founded by Paul Schimmel, Xiang-Lei Yang and Bruce Beutler on September 8, 2005 and is headquartered in San Diego, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

aTyr Pharma (LIFE) reports robust Q4 earnings, advances lead candidate

aTyr Pharma (LIFE) is well-positioned with a strong financial standing, a focus on innovative drug development for inflammatory diseases, and ongoing clinical trials for lead candidate efzofitimod targeting ILD and pulmonary sarcoidosis. While facing challenges in addressing analyst inquiries, the company has opportunities to advance its pipeline and leverage its financial resources for future growth.

aTyr Pharma progresses efzofitimod for ILD treatment, eyes transformative growth

aTyr Pharma's strong performance in advancing efzofitimod, solid financial position, and focus on innovation position them well for future growth and success
While facing challenges in pivotal studies and program management, the company's opportunities in pipeline expansion and disruptive drug discovery set a positive trajectory

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

SAN DIEGO, Dec. 24, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the appointment of Danielle Campbell to Vice President, Human Resources. Ms. Campbell will serve as a member of the company's executive leadership team and oversee all aspects of human resources strategies and functions, including organizational development, talent management and talent acquisition initiatives.

aTyr Pharma Appoints Danielle Campbell as Vice President of Human Resources

Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform. Novel engineering approach accelerates generation of new antibody candidates from tRNA synthetase platform.

aTyr Pharma to Present at Antibody Engineering & Therapeutics Conference

SEOUL, South Korea--(BUSINESS WIRE)---- $LIFE #DEVITA--DEVITA Global (“DEVITA”) together with the Bodi Insurance Group (“Bodi Insurance”) have agreed on a cooperation partnership for the joint development of a decentralized health data sharing economy by employing blockchain technology to create a network of trust on which platform participants, characterized as either “Data Owner” or “Data User”, can securely store and exchange personal health data. This agreement comes at a time when the global health insuranc

DEVITA Global Joins Hands With Bodi Insurance Group, Mongolia's Premier Insurance Provider, to Advance a Decentralized Health Data Sharing Economy

The mean of analysts' price targets for Atyr Pharma (LIFE) points to an 111.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Atyr Pharma (LIFE) Could Rally 112%: Here's is How to Trade

aTyr Pharma, Inc. (LIFE) CEO Sanjay Shukla on Q3 2021 Results - Earnings Call Transcript

Atyr Pharma (LIFE) delivered earnings and revenue surprises of 20.75% and -100.00%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Atyr Pharma (LIFE) Reports Q3 Loss, Misses Revenue Estimates

Positive results reported from Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis provided proof-of-concept for ATYR1923 and validation for tRNA synthetase biology platform and NRP2 target.

aTyr Pharma Announces Third Quarter 2021 Results and Provides Corporate Update

Findings provide key insights into ATYR2810's potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance.

aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting

Atyr Pharma (LIFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Atyr Pharma (LIFE) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Investors need to pay close attention to aTyr Pharma (LIFE) stock based on the movements in the options market lately.

Do Options Traders Know Something About aTyr Pharma (LIFE) Stock We Don't?

SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will participate in a fireside chat as part of the Piper Sandler Virtual Investor Day: Developing Therapeutics for Lung Indications on Friday, October 15, 2021, at 9:00am ET / 6:00am PT.

aTyr Pharma to Participate in Piper Sandler Investor Lung Day

SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that the company will present a poster at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, which is being held November 10 – 14, 2021 in Washington, DC, and virtually.

aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting

SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced the closing of an underwritten public offering of 10,781,250 shares of its common stock at a public offering price of $8.00 per share, which included the full exercise of the underwriters' option to purchase additional shares. The gross proceeds to aTyr from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses, are $86.3 million. All of the shares sold in the offering were sold by aTyr.

aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

AMC Entertainment

Peabody Energy

The last two weeks haven't exactly been ideal for the major US indices. Since the end of August, the Dow Jones Industrial Average, the S&P 500, and the Nasdaq 100 have been down 1.54%, 0.93%, and 0.51%, respectively.

What US Stocks Are The Largest Gainers In 2021?

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, which is being held from September 20 – 23, 2021.

aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that it has commenced an underwritten public offering of shares of its common stock. In addition, aTyr expects to grant the underwriters a 30-day option to purchase additional shares of its common stock. All of the shares to be sold in the offering are to be sold by aTyr. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

aTyr Pharma Announces Proposed Public Offering of Common Stock

aTyr Pharma (LIFE) soars following the announcement of positive results from its phase Ib/IIa study of its lead candidate, ATYR1923, for pulmonary sarcoidosis.

aTyr (LIFE) Surges on Positive Data on Lead Candidate ATYR1923

Atyr Pharma (LIFE) stock is soaring higher on Tuesday after the company released positive data from a recent clinical trial. The post LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soar on Study Results appeared first on InvestorPlace.

LIFE Stock: 7 Things to Know About Biotech aTyr Pharma as Shares Soar on Study Results

aTyr Pharma Inc (NASDAQ: LIFE) is trading significantly higher Tuesday after multiple analyst firms maintained bullish ratings on the stock and raised their respective price targets following the company's announcement that the Phase 1b/2a clinical trial of ATYR1923 in pulmonary sarcoidosis met its primary endpoint. HC Wainwright & Co. analyst Joseph Pantginis maintained aTyr Pharma with a Buy rating and raised the price target from $13 to $18.

Why aTyr Pharma Shares Are Continuing To Surge Higher Today

aTyr says it plans to meet with the FDA to present its data on ATYR1923, a potential treatment for pulmonary sarcoidosis.

A small pharmaceutical company has surged 137% in 2 days after positive results in trials for lung disease treatment

H.C. Wainwright increased the price target on ATyr Pharma (NASDAQ:LIFE) to $18 from $13, with the Buy rating unchanged, implying more than 120% upside. Today, the Company reported positive data from a pulmonary sarcoidosis trial evaluating ATYR1923.

Why Did Wainwright Beef Up ATyr Pharma's Price Target?

The stock price of aTyr Pharma Inc (NASDAQ: LIFE) significantly increased today. This is why it happened.

LIFE Stock: Why It Significantly Increased Today

Today, some news of positive clinical trial results for one of aTry's leading drug candidates has sent LIFE stock surging. The post LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?

LIFE Stock: What Is the Clinical Trial News Sending aTyr Pharma Soaring?

ATyr Pharma Inc (NASDAQ: LIFE) has announced positive results from its Phase 1b/2a trial evaluating its lead therapeutic candidate, ATYR1923, in pulmonary sarcoidosis, a major form of interstitial lung disease. In 37 patients, ATYR1923 was safe and well-tolerated at all doses with no drug-related serious adverse events or signal of immunogenicity.

Why Are ATyr Pharma's Shares Trading Higher Today?

Trial met primary endpoint, ATYR1923 was safe and well-tolerated.

News for aTyr Pharma Stock (LIFE)